The company has exclusive rights to the specific treatment of the drug we're trialing in animals and humans. If it works we will go gangbusters. Profits from epichem seem to be enough to keep these trials going. The canine version of the drug has already been designed to be in a gel capsule form. All we need is a producer and distributor, or a big pharma to come in and partner with us to push it out commercially. Either way, two companies with big potential - you are far better off than some other biotechs out there. Lots of promise.
Epichem, page-30
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |